Primary or metastatic melanoma, gastrointestinal tumor, breast cancer, ovarian cancer, pancreatic cancer, lung cancer, at least one lesion can be removed.
Conditions
Interventions
Case series:Neoantigen complex peptide loaded DCs.
Sponsors
Gansu Provincial Hospital
Eligibility
Sex/Gender
All
Age
15 Years to 65 Years
Inclusion criteria
Inclusion criteria: 1. Primary or metastatic melanoma, gastrointestinal tumor, breast cancer, ovarian cancer, pancreatic cancer, lung cancer, at least one lesion can be removed; 2. RECIST 1.1 is the standard for the measurement and evaluation of metastatic disease; 3. Pathological laboratory diagnosis of metastatic carcinoma; 4. All patients were not satisfied with the conventional treatment; 5. Asymptomatic patients with 3 or fewer brain metastases ( 8.0g/dl, CD4+ cell count > 200/L without the support of granulocyte colony stimulating factor; 11. When patients receive the vaccine, they must undergo more than 4 weeks of systematic treatment, and their toxicity must be restored to level 1 or less (except for toxicity such as alopecia areata or vitiligo). Note: the patient may have undergone minor surgery in the past 3 weeks, as long as all toxicity is restored to grade 1 or less; 12. Pre-survival period 6 months; 13. Ability to understand and willingness to sign a written informed consent.
Exclusion criteria
Exclusion criteria: 1. Pregnant or lactating women, women of reproductive age must test negative for pregnancy test within 7 days before enrollment; 2. Primary immunodeficiency of any kind (e.g., severe combined immunodeficiency disease); 3. Concomitant opportunistic infection (the experimental treatment evaluated in this protocol depends on the complete immune system). Patients with compromised immunity were less responsive to experimental treatments and more sensitive to their toxicity; 4. Active systemic infection (e.g. requiring anti-ineffective treatment), coagulation disorder or any other active major disease. Patients surveyed by other institutions.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Disease free survival; | — |
Secondary
| Measure | Time frame |
|---|---|
| Over survival;Tumor marker; | — |
Countries
China
Contacts
Public ContactXu Xianghong
Gansu Provincial Hospital
Outcome results
None listed